The estimated Net Worth of Duane Nash is at least $683 mil dollars as of 12 May 2022. Dr Nash owns over 10,000 units of Immunic stock worth over $33,489 and over the last 10 years he sold IMUX stock worth over $287,039. In addition, he makes $362,639 as Exec. Chairman at Immunic.
Dr has made over 17 trades of the Immunic stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of IMUX stock worth $50,300 on 12 May 2022.
The largest trade he's ever made was exercising 22,157 units of Immunic stock on 2 December 2019 worth over $33,679. On average, Dr trades about 1,917 units every 77 days since 2014. As of 12 May 2022 he still owns at least 22,032 units of Immunic stock.
You can see the complete history of Dr Nash stock trades at the bottom of the page.
Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A is the Exec. Chairman at Immunic.
As the Exec. Chairman of Immunic, the total compensation of Dr A at Immunic is $362,639. There are 6 executives at Immunic getting paid more, with Daniel Vitt having the highest compensation of $2,383,930.
Dr A is 50, he's been the Exec. Chairman of Immunic since . There are 12 older and 3 younger executives at Immunic. The oldest executive at Immunic, Inc. is Tamar Howson, 72, who is the Independent Director.
Duane's mailing address filed with the SEC is 1200 AVENUE OF THE AMERICAS, SUITE 200, , NEW YORK, NY, 10036.
Over the last 5 years, insiders at Immunic have traded over $174,861 worth of Immunic stock and bought 176,506 units worth $558,583 . The most active insiders traders include Barclay A Phillips, Joerg Neermann y Duane Nash. On average, Immunic executives and independent directors trade stock every 74 days with the average trade being worth of $15,244. The most recent stock trade was executed by Daniel Vitt on 26 February 2024, trading 14,000 units of IMUX stock currently worth $18,340.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Immunic executives and other stock owners filed with the SEC include: